Aimei Vacin Biopharm (zhejiang) Co., Ltd.

This early-stage trial tests a new tetanus vaccine in 80 adults aged 18 and older. Participants receive one dose to check for side effects and measure immune response. The study is not yet recruiting and aims to ensure the vaccine is safe before larger trials.